What is SOLV's intrinsic value?

TickerWorth's blended fair value for Solventum Corporation (SOLV) is $104.15 per share, versus a market price of $85.81 (priced within our range of $53.32 – $127.57).

Is SOLV overvalued or undervalued?

Priced within our range of $53.32 – $127.57 at $85.81. We don't call SOLV overvalued or undervalued from a range. This is an educational estimate, not advice.

What discount rate is used for SOLV?

A WACC of 8.4% and a terminal growth rate of 2.5%.

Is Solventum stock undervalued?

TickerWorth's fair value for Solventum Corporation (SOLV) is $104.15 against a market price of $85.81. Our read: Priced within our range of $53.32 – $127.57. This is a model estimate, not investment advice.

Solventum (SOLV) DCF valuation and fair value

Our fair value for Solventum Corporation (SOLV) is $104.15, built on a 8.4% discount rate (WACC) and 2.5% terminal growth. It blends our discounted-cash-flow model with other valuation lenses. Every assumption is listed on this page with its source.

What growth is priced into Solventum stock?

Today's price implies revenue growth of −1.3% a year for 5 years; our model assumes 3.9% a year on average over the same horizon. This is a reverse DCF: it holds our cash-flow model's other inputs and solves for the revenue growth that makes the model equal today's price of $85.81. A model estimate, not investment advice.

Solventum (SOLV) insider trading

The most recent insider filing (SEC Form 4) for Solventum Corporation (SOLV): Hanson Bryan C, Director, Chief Executive Officer, option exercise on 2026-09-01. The latest filings are listed on this page. A disclosure, not a signal to trade.

SOLV · Intrinsic value

Is Solventum Corporation (SOLV) overvalued or undervalued?

Name: Solventum Corporation (SOLV) DCF intrinsic value
Creator: TickerWorth

Solventum Corporation (SOLV) trades at the delayed market price of $85.81 a share. That price already implies revenue growth of −1.3% a year for 5 years. TickerWorth's fair value is $104.15 a share (priced within our range of $53.32 – $127.57). We do not call it over- or undervalued from inside our range.

Model by Miraaj Patel · generated from a hand-researched model · Updated Oct 19, 2026 · How these pages are made

Open full SOLV analysis

Is SOLV fairly valued?

Backup data source

This price comes from our backup market-data feed.

Fair value: $104.15
Market price: $85.81
Upside to fair value: +21.4%
Verdict: Priced within our range of $53.32 – $127.57

Price as of 19 Oct 2026, 13:16 UTC · Prices are delayed.

Fair value against the delayed market price: Priced within our range of $53.32 – $127.57.

Reverse DCF: Today's price implies revenue growth of −1.3% a year for 5 years; our model assumes 3.9% a year on average over the same horizon.

What is SOLV's TickerWorth Score?

C51/100

Middle of the pack — real strengths and real weaknesses

Compared with Healthcare companies in US

Its strongest point: looks cheap on the numbers. Its weakest: balance sheet looks stretched.

Value · 68 of 100
Cheaper than 68% of Healthcare companies in US
Price vs worth · 67 of 100
Quality · 62 of 100
More profitable than 62% of Healthcare companies in US
Financial health · 14 of 100
Financially stronger than 14% of Healthcare companies in US
Growth · 22 of 100
Growing faster than 22% of Healthcare companies in US
Momentum · 58 of 100
Outperformed 58% of Healthcare companies in US over the past year

Confidence: High confidence · Scored 19 Oct 2026, 13:16 UTC

Get the Undervalued Company of the Week.

Where the numbers come from

Hand-researched model

What the modeller flagged

YEAR-1 FCF IS NOT COMPARABLE WITH REPORTED FCF. Model Year-1 unlevered FCF is ~$711M against FY2025 reported FCF of -$10M and FY2026 guidance of $200-300M. Most of the difference is definitional: the model's FCF is before ~$200M of after-tax interest, and before Bair Hugger payments, P&F-sale taxes and transaction costs, which sit in net debt or are already behind the company. The rest (~$250M) is 2026 cash drag the model does not capture — the ERP pull-forward in receivables, TSA-exit payments and higher incentive pay. Discounting that one-year gap costs ~$1.3/share; it is flagged, not modelled.
TERMINAL VALUE IS ~80% OF ENTERPRISE VALUE. Years 1-2 are deliberately depressed by separation costs, so most of the value comes from the steady state after the transformation. The answer is a bet on Solventum reaching and holding a ~23% operating margin.
THE AMORTIZATION CHOICE IS WORTH ~$24/SHARE. The EBIT margin excludes the ~$312M/yr of acquired-intangible amortization (mostly 3M's 2019 KCI deal), treating it as non-cash and not tax-relevant. If Solventum turns into a serial acquirer, that is too generous; charging it as a cost lowers the value to ~$85.
MARGIN PATH LEANS ON MANAGEMENT'S LRP. The 23% terminal margin is inside the 23-25% 2028 target, but that target INCLUDES the 36-41%-margin HIS business. If HIS is sold and the proceeds are returned, the business left behind will earn less and be valued on its own. The Q1 2027 investor day will reset the number.
2026 IS NOISY IN BOTH DIRECTIONS: a one-off ~$100M IEEPA tariff refund and ~$125M of ERP pull-forward sales flattered Q2, and Q3 sales growth is guided to roughly -3% to -4% as the pull-forward reverses. Year 1 uses the full-year guidance, which already nets these out.
SBC ($161M in FY2025, $89M in H1 2026) is NOT excluded from Solventum's adjusted figures and stays expensed inside the margin; dilution is captured by the weighted diluted share count.
Credit ratings were described by management, not checked against agency releases; a downgrade would raise the 6.4% cost of debt.

SOLV DCF valuation, input by input

TickerWorth's fair value for Solventum Corporation (SOLV) is $104.15 a share, against the delayed market price of $85.81 (priced within our range of $53.32 – $127.57). We do not call it over- or undervalued from inside our range. It is a model estimate, and every input behind it is sourced below. This is an educational model, not a price target or a recommendation.

Read the full reasoning

One of the lenses behind that blended figure is a discounted-cash-flow model, which on its own values SOLV at about $108.53 per share. The rest of this page walks through that DCF — its assumptions, reverse-DCF and discount-rate sensitivity — because it is the auditable anchor of the blend.

The valuation discounts Solventum Corporation's projected free cash flows at a weighted-average cost of capital (WACC) of 8.4%, with a long-run terminal growth rate of 2.5%. About 80% of the enterprise value comes from the terminal value — the portion beyond the explicit forecast window — which is typical for a stable, cash-generative business and a reminder that small changes in the discount rate or terminal growth assumption swing the intrinsic value meaningfully.

Running the DCF in reverse — solving for the growth the current price already assumes — the market is implying roughly -1.3% annual revenue growth for SOLV. Our base case instead compounds to about 3.9% a year over the same forecast, so the market is pricing in slower growth than our base case. The reverse-DCF is a quick sanity check: it reframes 'is this stock cheap?' as 'do I believe the growth the price requires?' rather than arguing over a single point estimate of fair value.

Sensitivity matters more than any single number. Across a reasonable band of discount-rate assumptions, SOLV's modeled DCF value ranges from about $68.65 to $207.51 per share. If that range still sits below today's price, the market is optimistic relative to the model across the whole band; if it brackets the price, the stock is roughly fairly valued on our assumptions. Use the interactive slider to see exactly where your own cost-of-capital view lands.

How to read this page: the DCF fair value is what Solventum Corporation would be worth if its cash flows grow as modeled and are discounted at the stated WACC. The assumptions table shows every input and its source; the reverse-DCF shows what the market believes; the sensitivity band shows how fragile the answer is. None of this is investment advice — it is a transparent, auditable framework for forming your own view of SOLV's intrinsic value. Figures update as new filings and prices come in.

Every input behind SOLV's DCF

Input	Value	Source
Base-year revenueSolventum Q4 2025 earnings release, 8-K Ex-99.1 (accession 0001964738-26-000005, filed 2026-02-26); FY2025 10-K (accession 0001964738-26-000007): CONTINUING BUSINESS ONLY. Reported FY2025 net sales were $8,325M, but that includes $497M of Purification & Filtration (P&F) sales for January-August 2025; P&F was sold to Thermo Fisher on 2025-09-01 for ~$4B cash (10-Q Note 3). $8,325M - $497M = $7,828M = MedSurg $4,817M + Dental $1,349M + Health Information Systems $1,360M + All Other $302M (the retained drinking-water business and legacy 3M supply agreements). Reported FY2025 growth of +0.9% is meaningless for that reason; organic growth was +3.3%. Health Information Systems (HIS) is KEPT IN this base even though Solventum announced on 2026-08-05 its intent to separate it, because no structure, buyer or date exists yet (see special_cases). CROSS-CHECK: H1 2026 revenue $4,216M vs H1 2025 ex-P&F $3,862M ($4,231M - $369M) = +9.2%, of which ~$125M (~3.2 pts) is customers ordering ahead of the July 2026 US ERP cutover and will reverse in Q3, plus Acera (acquired Dec 2025) and ~1.8 pts of currency.	$7,828,000,000	Solventum Q4 2025 earnings release, 8-K Ex-99.1 (accession 0001964738-26-000005, filed 2026-02-26); FY2025 10-K (accession 0001964738-26-000007): CONTINUING BUSINESS ONLY. Reported FY2025 net sales were $8,325M, but that includes $497M of Purification & Filtration (P&F) sales for January-August 2025; P&F was sold to Thermo Fisher on 2025-09-01 for ~$4B cash (10-Q Note 3). $8,325M - $497M = $7,828M = MedSurg $4,817M + Dental $1,349M + Health Information Systems $1,360M + All Other $302M (the retained drinking-water business and legacy 3M supply agreements). Reported FY2025 growth of +0.9% is meaningless for that reason; organic growth was +3.3%. Health Information Systems (HIS) is KEPT IN this base even though Solventum announced on 2026-08-05 its intent to separate it, because no structure, buyer or date exists yet (see special_cases). CROSS-CHECK: H1 2026 revenue $4,216M vs H1 2025 ex-P&F $3,862M ($4,231M - $369M) = +9.2%, of which ~$125M (~3.2 pts) is customers ordering ahead of the July 2026 US ERP cutover and will reverse in Q3, plus Acera (acquired Dec 2025) and ~1.8 pts of currency.
Base EBIT marginSolventum Q4 2025 earnings release, 8-K Ex-99.1 (accession 0001964738-26-000005) — FY2025 non-GAAP reconciliation and segment table: DERIVED, and the definition matters: this model's 'EBIT' is operating income BEFORE amortization of acquired intangibles (see da_pct_revenue for why) but AFTER every real cash cost, including the 3M-separation and restructuring spend that Solventum's 'adjusted' figure leaves out. Build: adjusted operating income $1,709M - P&F segment operating income $96M = $1,613M (20.6% of $7,828M); less 3M spin-off/separation costs $579M, restructuring $80M and Acera deal costs $12M = $942M = 12.0%. TIES TO GAAP: GAAP operating income $2,181M - $1,549M gain on the P&F sale + $312M amortization - $96M P&F operating income + $44M P&F-sale costs + $51M litigation costs = $943M. Litigation is handled in net debt, not here. The reported GAAP margin of 26.2% is NOT usable — 18.6 points of it is the one-off gain on selling P&F. CROSS-CHECK H1 2026: adjusted operating income $1,019M - separation $308M - restructuring $82M - Acera $21M - HIS separation $6M + P&F TSA mark-up $12M = $614M / $4,216M = 14.6%, flattered by ~$100M of IEEPA tariff refunds and the ERP pull-forward in Q2.	12.0%	Solventum Q4 2025 earnings release, 8-K Ex-99.1 (accession 0001964738-26-000005) — FY2025 non-GAAP reconciliation and segment table: DERIVED, and the definition matters: this model's 'EBIT' is operating income BEFORE amortization of acquired intangibles (see da_pct_revenue for why) but AFTER every real cash cost, including the 3M-separation and restructuring spend that Solventum's 'adjusted' figure leaves out. Build: adjusted operating income $1,709M - P&F segment operating income $96M = $1,613M (20.6% of $7,828M); less 3M spin-off/separation costs $579M, restructuring $80M and Acera deal costs $12M = $942M = 12.0%. TIES TO GAAP: GAAP operating income $2,181M - $1,549M gain on the P&F sale + $312M amortization - $96M P&F operating income + $44M P&F-sale costs + $51M litigation costs = $943M. Litigation is handled in net debt, not here. The reported GAAP margin of 26.2% is NOT usable — 18.6 points of it is the one-off gain on selling P&F. CROSS-CHECK H1 2026: adjusted operating income $1,019M - separation $308M - restructuring $82M - Acera $21M - HIS separation $6M + P&F TSA mark-up $12M = $614M / $4,216M = 14.6%, flattered by ~$100M of IEEPA tariff refunds and the ERP pull-forward in Q2.
Forecast revenue growthESTIMATEAssumption — TickerWorth's 5-year explicit forecast	5% → 4% → 4% → 4% → 3%	ESTIMATEAssumption — TickerWorth's 5-year explicit forecast
Risk-free rateUS 10Y Treasury constant maturity (FRED DGS10): 5.24% on 2026-10-01, the latest published observation; program-wide input shared by every researched model in this run.	5.2%	US 10Y Treasury constant maturity (FRED DGS10): 5.24% on 2026-10-01, the latest published observation; program-wide input shared by every researched model in this run.
BetaESTIMATEAssumption — normalized estimate (published Yahoo/yfinance beta 0.703): NORMALIZED UP from the published 0.703 — CONSERVATIVE (raises WACC, lowers value). Reason: Solventum has only traded since 2024-04-01, so a '5Y monthly' beta is really ~30 monthly observations, dominated by spin-off flows; and the company carries ~26% debt in its capital structure, an uncapped Bair Hugger litigation indemnity and two separations in flight. 0.85 sits between the published figure and the ~0.9-1.0 typical of levered diversified medtech. At the published 0.703 the value is about $123; at 1.0 about $96; the market price implies about 1.12.	0.85	ESTIMATEAssumption — normalized estimate (published Yahoo/yfinance beta 0.703): NORMALIZED UP from the published 0.703 — CONSERVATIVE (raises WACC, lowers value). Reason: Solventum has only traded since 2024-04-01, so a '5Y monthly' beta is really ~30 monthly observations, dominated by spin-off flows; and the company carries ~26% debt in its capital structure, an uncapped Bair Hugger litigation indemnity and two separations in flight. 0.85 sits between the published figure and the ~0.9-1.0 typical of levered diversified medtech. At the published 0.703 the value is about $123; at 1.0 about $96; the market price implies about 1.12.
Terminal growthESTIMATEAssumption — house default: House default 2.5% (roughly long-run nominal GDP), kept for comparability. Reasonable for hospital consumables and dental, whose volumes track ageing and procedure counts; the 4-5% LRP organic target is a medium-term claim, not a perpetual one. Must stay below WACC (8.35%). At 2.0% the value falls ~$9.	2.5%	ESTIMATEAssumption — house default: House default 2.5% (roughly long-run nominal GDP), kept for comparability. Reasonable for hospital consumables and dental, whose volumes track ageing and procedure counts; the 4-5% LRP organic target is a medium-term claim, not a perpetual one. Must stay below WACC (8.35%). At 2.0% the value falls ~$9.
Diluted sharesSolventum Q2 2026 10-Q (accession 0001964738-26-000047, filed 2026-08-05): Q2 2026 weighted-average diluted shares 173.3M (H1 174.4M; FY2025 ~175M). CONSERVATIVE: the weighted average lags the buyback — Solventum repurchased 4.8M shares for $355M in H1 2026 ($288M in Q2 alone), leaving 170.1M outstanding at 2026-06-30. On ~170.7M (outstanding plus ~0.6M of dilutive awards) the value would be ~$1.65 higher. Repurchases after June 30 are not yet reported.	173M	Solventum Q2 2026 10-Q (accession 0001964738-26-000047, filed 2026-08-05): Q2 2026 weighted-average diluted shares 173.3M (H1 174.4M; FY2025 ~175M). CONSERVATIVE: the weighted average lags the buyback — Solventum repurchased 4.8M shares for $355M in H1 2026 ($288M in Q2 alone), leaving 170.1M outstanding at 2026-06-30. On ~170.7M (outstanding plus ~0.6M of dilutive awards) the value would be ~$1.65 higher. Repurchases after June 30 are not yet reported.
Market priceBackup price feed · as of 2026-10-19 13:16 UTC	$85.81	Backup price feed · as of 2026-10-19 13:16 UTC

Change SOLV's assumptions

The discount-rate dial and the editable model

Pro

Change growth, margin and WACC yourself — Pro (7-day free trial, card required).

Start free trial Try it on Apple

What does Solventum Corporation do?

What does it do?

Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems. It operates in the Medical Instruments & Supplies industry (Healthcare sector), headquartered in United States. The company employs roughly 20,584 people.

How does it make money?

The business turns $8.3B in annual revenue into profit. Out of every $100 of sales, about $10 is left as operating profit (operating margin of 9.8%), after a 55% gross margin on the products/services it sells. After all costs, taxes and interest, 17.3% of revenue becomes bottom-line net profit.

Is it financially healthy?

Financially it looks stretched: carries moderate debt (1.1× equity), can just cover its short-term bills (1.0× current ratio), and is currently profitable.

Who at SOLV filed insider trades?

Recent insider filings for Solventum Corporation
Date	Insider	Relationship	What happened	Value	Filing
1 Sept 2026	Hanson Bryan C	Director, Chief Executive Officer	Option exercise	—	Form 4 for Hanson Bryan C (opens sec.gov in a new tab)
1 Sept 2026	Hanson Bryan C	Director, Chief Executive Officer	Shares withheld (tax)	$2,407,264.60	Form 4 for Hanson Bryan C (opens sec.gov in a new tab)
13 May 2026	Gomez Tammy L	Chief Human Resources Officer	Option exercise	—	Form 4 for Gomez Tammy L (opens sec.gov in a new tab)
13 May 2026	Gomez Tammy L	Chief Human Resources Officer	Shares withheld (tax)	$124,115.88	Form 4 for Gomez Tammy L (opens sec.gov in a new tab)
13 May 2026	McMillan Wayde D.	Chief Financial Officer	Option exercise	—	Form 4 for McMillan Wayde D. (opens sec.gov in a new tab)
13 May 2026	McMillan Wayde D.	Chief Financial Officer	Shares withheld (tax)	$327,701.64	Form 4 for McMillan Wayde D. (opens sec.gov in a new tab)

A disclosure, not a signal to trade. Source: SEC EDGAR (Form 4). Older filings and the 90-day buying-and-selling read are part of Pro. See plans

Common questions

What is SOLV's intrinsic value?
TickerWorth's blended fair value for Solventum Corporation (SOLV) is $104.15 per share, versus a market price of $85.81 (priced within our range of $53.32 – $127.57).
Is SOLV overvalued or undervalued?
Priced within our range of $53.32 – $127.57 at $85.81. We don't call SOLV overvalued or undervalued from a range. This is an educational estimate, not advice.
What discount rate is used for SOLV?
A WACC of 8.4% and a terminal growth rate of 2.5%.
Is Solventum stock undervalued?
TickerWorth's fair value for Solventum Corporation (SOLV) is $104.15 against a market price of $85.81. Our read: Priced within our range of $53.32 – $127.57. This is a model estimate, not investment advice.
Solventum (SOLV) DCF valuation and fair value
Our fair value for Solventum Corporation (SOLV) is $104.15, built on a 8.4% discount rate (WACC) and 2.5% terminal growth. It blends our discounted-cash-flow model with other valuation lenses. Every assumption is listed on this page with its source.
What growth is priced into Solventum stock?
Today's price implies revenue growth of −1.3% a year for 5 years; our model assumes 3.9% a year on average over the same horizon. This is a reverse DCF: it holds our cash-flow model's other inputs and solves for the revenue growth that makes the model equal today's price of $85.81. A model estimate, not investment advice.
Solventum (SOLV) insider trading
The most recent insider filing (SEC Form 4) for Solventum Corporation (SOLV): Hanson Bryan C, Director, Chief Executive Officer, option exercise on 2026-09-01. The latest filings are listed on this page. A disclosure, not a signal to trade.